Beyond Air, Inc. (XAIR): Cost of Revenue

Annual figures by period end, from SEC filings.

$7.43M

Year ended 2026-03-31

$7.37M

Trailing 12 months to 2026-06-30

+137.4%

3-year compound annual growth

2023-03-31 Cost of Revenue (USD) 2026-03-31

Period ended	Cost of Revenue	Change YoY	Source filing
2026-03-31	$7.43M	+38.4%	2026-06-26, From 2025-04-01
2025-03-31	$5.37M	+117.7%	2026-06-26, From 2024-04-01
2024-03-31	$2.47M	+344.3%	2025-06-20, From 2023-04-01
2023-03-31	$555.0K	n/a	2024-06-24, From 2022-04-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Beyond Air, Inc. (XAIR)	2026-03-31	$7.43M	+38.4%
INVO Fertility, Inc. (IVF)	2025-12-31	$30.6K	+150.6%
InspireMD, Inc. (NSPR)	2025-12-31	$6.33M	+15.0%
Encision Inc (ECIA)	2025-03-31	$3.04M	-11.8%
Neuroone Medical Technologies Corp (NMTC)	2025-09-30	$3.96M	+66.7%
Medinotec Inc. (MDNC)	2026-02-28	$4.60M	+7.1%
Nexgel, Inc. (NXGL)	2025-12-31	$6.91M	+16.4%
Picard Medical, Inc. (PMI)	2025-12-31	$5.14M	+14.2%
Lucid Diagnostics Inc. (LUCD)	2025-12-31	$6.67M	-6.0%

Compare XAIR, IVF, NSPR, ECIA side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗